Thank you for subscribing!
Next Investors Mar 06, 2023
The sparsentan drug, which recently received accelerated FDA approval, and priced at US$120,000 per year, per patient, could act as a benchmark for Dimerix (ASX:DXB) pricing and potential deal value in negotiations with major pharmaceutical companies.
Finfeed Oct 15, 2021
Dimerix (ASX:DXB) is moving fast with its Covid-19 trials, and today announced that this COVID-19 Phase III Study will expand to Australia.
Next Investors Sep 27, 2021
On Friday last week, DXB announced that the main drug regulator in India has recommended approval for DXB’s Phase III clinical trials on COVID-19 treatment, specifically for patients with respiratory complications intended for hospitalisation — its CLARITY 2.0 study.
Finfeed Sep 24, 2021
The main drug regulator in India has recommended approval for Dimerix Ltd's (ASX:DXB) Phase 3 clinical trials on its COVID-19 treatment for patients with respiratory complications.
Get expert stock analysis direct in your inbox
Finfeed Aug 26, 2021
Yesterday Dimerix (ASX:DXB) announced its first “ethics submission” in Australia. Once approved, the patient recruitment process can begin for the Phase 3 trials. We will provide our commentary at every step in the process.
Finfeed Aug 16, 2021
Everything that you need to know about investing in Dimerix (ASX:DXB). A comprehensive summary of 9 reasons why we have invested in DXB. Upcoming projects, and milestones.
Join Our Mailing List
